On May 27, 2021 Cellesce reported that has carried out a study in collaboration with Cardiff University to assess organoid size and cell count from 3D image analysis (Press release, Cellesce, MAY 27, 2021, View Source [SID1234580680]). Whilst the improved predictive power of patient-derived organoids (PDOs) have the potential to replace 2D assays in drug discovery the challenge for organoid users is to fully extract, exploit and understand the increased complexity of 3D in vitro models. 3D image analysis may well provide a means to address that challenge.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Many of the practical limitations have already been overcome by recent advances in microscopy, leading to improvements in 3D image resolution, speed of imaging, data acquisition and dedicated software for high-content, high throughput assays. This technology can be used to quantify changes in gross organoid morphology, such as size and shape and also detect subtle, cellular, drug-induced alterations. Multi-parametric, image-based analysis can lead to an understanding of the relationship between the morphology of 3D PDOs and the underlying cell biology Badder et al. 2020, PLOS ONE.